Effect Of Oral DPP-4 Inhibitor Treatment To Type 2 Diabetic Patients

ASIA unversity > 資訊學院 > 生物資訊與醫學工程學系 > 博碩士論文 > Item 310904400/10918

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/10918

题名:	Effect Of Oral DPP-4 Inhibitor Treatment To Type 2 Diabetic Patients
作者:	CHEN RUI MING
贡献者:	Department of Bioinformatics
关键词:	Diabetes;Dipeptidyl Peptidase-IV Inhibitor;HbA1c
日期:	2010
上传时间:	2010-11-08 02:33:11 (UTC+0)
出版者:	Asia University
摘要:	Diabetes affects the health conditions of at least 200 million people worldwide, and one person died from diabetes every 10 second around the world; IDF expects that by 2025, the death will increase to 3300 million.In Taiwan, the cause of death statistics announced by the Department of Health, Taiwan in year 98, showed that the diabetic has become the fifth leading cause of death, and accounted for 5.8% of overall mortality (Taiwan Department of Health, 2009); diabetes have become one of chronic diseases so that the bad control of diabetes would cause many complications. The latest two oral hypoglycemic medicines (Dipeptidyl Peptidase-IV Inhibitor) introduced into Taiwan, the pyrrolidine derivatives, can inhibit the activity of DPP IV, avoid endogenous GLP-1 (glucagon-likepeptide-1), and the breakdown of GIP (glucose-dependent insulinotropic polypeptide) to reduce high blood sugar, not to affect body weight, and easily to lead to low blood sugar level.
显示于类别:	[生物資訊與醫學工程學系 ] 博碩士論文

文件中的档案:

档案	大小	格式	浏览次数
	0Kb	Unknown	239	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.